当PIDD水平在肺癌细胞人为增加时，它们对顺铂耐药性增强。
When PIDD levels are artificially increased in human lung cancer cells, they become more resistant to cisplatin.
目的：建立人卵巢癌顺铂耐药细胞株COC1/DDP，探讨其耐药的机制。
Objective: To establish a cisplatin-resistant ovarian cancer cell line COC1/DDP, and investigate the mechanism of resistance.
顺铂的主要药理机制是损伤细胞DNA，肿瘤细胞DNA修复能力增强则会导致其对顺铂耐药。
The main mechanism of cisplatin is tumor cells death by damaging the DNA. The resistance to cisplatin is associated with the cell's increased ability of DNA repair.
目的探讨COC1/DDP和COC1中凋亡相关基因及凋亡相关蛋白的表达与人卵巢癌顺铂耐药的关系。
This study was designed to explore the role of apoptosis- associated genes and proteins on the chemoresistance in COC1/DDP.
现在，MIT癌症生物学家已经展现了耐药性是如何增加的，这项发现可能帮助研究员设计可以克服顺铂耐药性的新药。
Now, MIT cancer biologists have shown how that resistance arises, a finding that could help researchers design new drugs that overcome cisplatin resistance.
顺铂通常第一次给药时有效，它有一个主要的缺陷：肿瘤获得耐药性，而且重新开始生长。
While cisplatin is often effective when first given, it has a major drawback: Tumors can become resistant to the drug and start growing again.
临床试验表明，TPT与顺铂和紫杉醇无交叉耐药性。
Clinical non cross resistance had been demonstrated between TPT and cisplatin or paclitaxel.
顺铂(DDP)是肺癌治疗的常用化疗药物，然而，由于耐药的发生，常常导致肺癌化疗的失败，并限制了铂类药物的广泛应用。
Cisplatin (DDP) is widely applied to chemotherapeutic regimens for lung cancer. However, its application is limited usually by the failed therapy due to resistance.
顺铂(DDP)是肺癌治疗的常用化疗药物，然而，由于耐药的发生，常常导致肺癌化疗的失败，并限制了铂类药物的广泛应用。
Cisplatin (DDP) is widely applied to chemotherapeutic regimens for lung cancer. However, its application is limited usually by the failed therapy due to resistance.
应用推荐